Complicated but Successful Treatment of a Patient with Ataxia Telangiectasia and Pre-B-Acute Lymphoblastic Leukemia

Abstract

A general recommendation for dose modification in these patients group cannot be made due to the low number of patients suffering from AT and leukaemia. Central registration of these rare patients will potentially facilitate to develop effective chemotherapeutic strategies with tolerable toxicity.

Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen‐breakage syndrome): a retrospective survey

“…The general impression and sparse previous data on therapy outcome suggest that the prognosis of those children is dismal. Individual cases with extremely high therapy‐related toxicity were reported, leading to life‐threatening complications (Sandoval & Swift, 1998, 2003; Niehues et al , 2003; Ziino et al , 2006; Dembowska‐Baginska et al , 2009; Brummel et al , 2010). Moreover, because of the underlying DNA repair defect, any chemotherapy substantially increases the further risk of tumour development later in life.…”

Identifying ataxia‐telangiectasia in cancer patients: Novel insights from an interesting case and review of literature

“…Some gradually up titrated the dose as tolerated while taking care to limit doses of certain agents, such as methotrexate and cyclophosphamide. Durable complete remissions have been successfully achieved with modified dose chemotherapy regimens 41‐49 . The largest of these studies by Schoenaker et al 39 demonstrated no significant difference in remission rates for patients with T‐cell acute lymphoblastic leukemia receiving modified dose chemotherapy.…”

Detection of Acute Lymphoblastic Leukemia Involvement in Pleural Fluid in an Adult Patient with Ataxia Telangiectasia by Flow Cytometry Method

“…Because of increased chemosensitivity, the treatment of AT patients with malignancies requires extremely careful planning and caution with respect to the use of chemotherapy [9][10][11]. ALL, cancer of the white blood cells, is a heterogenous disease that mainly occurs due to the malignant cloning of lymphocytes.…”